Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Fuji
Healthtrust
Novartis
Medtronic
Mallinckrodt
Covington
US Department of Justice
Argus Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,952,340

« Back to Dashboard

Which drugs does patent 5,952,340 protect, and when does it expire?

Patent 5,952,340 protects KYTRIL and is included in one NDA.

This patent has twenty-five patent family members in nineteen countries.
Summary for Patent: 5,952,340
Title: Use of granisetron for the treatment of postoperative nausea and vomiting
Abstract:The present invention is directed to a method for the treatment of post-operative nausea and vomiting wherein granisetron is administered to a patient in need thereof.
Inventor(s): Sanger; Gareth John (Sawbridgeworth, GB), Davey; Philip Timothy (Bishop's Stortford, GB), Dott; Christopher Stuart (Reigate, GB)
Assignee: SmithKLine Beecham p.l.c. (Brentford, GB)
Application Number:08/525,521
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,952,340

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-004 Mar 11, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe POST OPERATIVE NAUSEA AND VOMITING ➤ Subscribe
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-001 Dec 29, 1993 DISCN Yes No ➤ Subscribe ➤ Subscribe POST OPERATIVE NAUSEA AND VOMITING ➤ Subscribe
Roche KYTRIL granisetron hydrochloride INJECTABLE;INJECTION 020239-002 Mar 11, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe POST OPERATIVE NAUSEA AND VOMITING ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,952,340

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9305593Mar 18, 1993
PCT Information
PCT FiledMarch 15, 1994PCT Application Number:PCT/EP94/00820
PCT Publication Date:September 29, 1994PCT Publication Number: WO94/21257

International Patents Family Members for US Patent 5,952,340

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1122570 ➤ Subscribe
China 1085079 ➤ Subscribe
Cyprus 2427 ➤ Subscribe
Germany 69431986 ➤ Subscribe
Denmark 0689437 ➤ Subscribe
European Patent Office 0689437 ➤ Subscribe
Canada 2158354 ➤ Subscribe
Australia 6377494 ➤ Subscribe
Austria 230596 ➤ Subscribe
Spain 2188611 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Merck
QuintilesIMS
UBS
US Army
Federal Trade Commission
McKesson
Julphar
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot